The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...

ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY ...

Related: Bristol Myers's stock pops as earnings top estimates and company raises guidance In September, Bristol Myers's shares rose after the FDA approved Cobenfy. The drug, previously called KarXT, ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on ...

Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.

She is one of the founders of Karuna, which took a similar approach to improving on current CNS therapies with the development of Cobenfy (xanomeline ... approved by the FDA last month.

The US could start catching up to Europe on biosimilars if the FDA removed the need for switching ... In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel ...